GlassScriptPhysician profile
Kerry Dewitt Shepherd
NPI 1952696528
$5,171.39
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $517 · 2022: $1,314 · 2023: $2,284 · 2024: $1,056.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,341.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,340.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,200.01 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $567.36 | 2021-2024 | Rexulti, Nuedexta, Abilify Mycite |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $509.96 | 2022-2024 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $404.38 | 2022-2024 | Austedo Xr, Uzedy, Austedo |
| Supernus Pharmaceuticals, INC. | $401.13 | 2022-2024 | Qelbree, Qelbree |
| Lundbeck LLC | $321.85 | 2021-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $293.73 | 2021-2024 | Trintellix |
| Alkermes, INC. | $246.87 | 2021-2023 | Vivitrol |
| Janssen Pharmaceuticals, INC | $223.48 | 2022-2024 | Spravato |
| Neurocrine Biosciences, INC. | $214.49 | 2021-2024 | Ingrezza |
| Corium, LLC | $182.45 | 2022-2024 | Azstarys |
| Almatica Pharma LLC | $135.37 | 2023-2024 | Loreev Xr |
| Axsome Therapeutics, INC. | $104.05 | 2023-2024 | Auvelity |
| Neos Therapeutics, LP | $69.16 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $62.02 | 2023 | Hetlioz, Fanapt |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $47.00 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $44.20 | 2023-2024 | |
| Indivior INC. | $31.60 | 2022-2023 | Sublocade |
| Philips North America LLC | $26.60 | 2021 | |
| Owp Pharmaceuticals, INC. | $24.57 | 2023 | Lamotrigine, Subvenite |
| Tris Pharma INC | $21.57 | 2024 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $21.13 | 2024 | |
| Jazz Pharmaceuticals INC. | $18.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kerry Shepherd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.